TY - JOUR T1 - Evaluation of patient experience for a computationally-guided intranasal spray protocol to augment therapeutic penetration JF - medRxiv DO - 10.1101/2021.08.31.21262495 SP - 2021.08.31.21262495 AU - Saikat Basu AU - Uzzam Ahmed Khawaja AU - Syed A A Rizvi AU - BoLiang Gong AU - Waiman Yeung AU - Marcos A Sanchez-Gonzalez AU - Gustavo Ferrer Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/01/2021.08.31.21262495.abstract N2 - The global respiratory outbreak in the form of COVID-19 has underlined the necessity to devise more effective and reproducible intranasal drug delivery modalities, that would also be user-friendly for adoption compliance. In this study, we have collected evaluation feedback from a cohort of 13 healthy volunteers, who assessed two different nasal spray administration techniques, namely the vertical placement protocol (or, VP), wherein the nozzle is held vertically upright at a shallow insertion depth of 0.5 cm inside the nasal vestibule; and the shallow angle protocol (or, SA), wherein the spray axis is angled at 45° to the vertical, with a vestibular insertion depth of 1.5 cm. The SA protocol is derived from published findings on alternate spray orientations that have been shown to enhance targeted delivery at posterior infection sites, e.g., the ostiomeatal complex and the nasopharynx. All study participants reported that the SA protocol offered a more gentle and soothing delivery experience, with less impact pressure. Additionally, 60% participants opined that the VP technique caused painful irritation. We also tracked the drug transport processes for the two spray techniques in a computed tomography-based nasal reconstruction; the SA protocol marked a distinct improvement in therapeutic penetration when compared to the VP protocol.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04790487Funding StatementSB was partially supported by the National Science Foundation, through the RAPID Grant 2028069. Any opinions, findings, and conclusions or recommendations presented here are, however, those of the authors and do not necessarily reflect NSF's views.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Volunteer feedback data was collected under written informed consent, as approved by the Institutional Ethics Committee at the Larkin Health System (South Miami, FL). For the in silico testing, the use of the archived and anonymized medical record was approved with exempt status by the Institutional Review Board of the University of North Carolina (UNC) at Chapel Hill, whereby the requirement of informed consent was waived for retrospective use of the de-identified scans in computational research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe simulation data for the intranasal drug delivery trends in CT-based anatomic domains is available on-request from the corresponding author (SB). ER -